Focused On-demand Library for Serine/threonine-protein kinase 35

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

CLP-36-interacting kinase 1; PDLIM1-interacting kinase 1; Serine/threonine-protein kinase 35 L1

Alternative UPACC:

Q8TDR2; B2RBM3; C7ENV8; Q2NKW6; Q5T3R1; Q5T3R2; Q96AB4; Q9BZ06


Serine/threonine-protein kinase 35, also known by its alternative names CLP-36-interacting kinase 1, PDLIM1-interacting kinase 1, and Serine/threonine-protein kinase 35 L1, plays a pivotal role in cellular signaling pathways. This kinase is involved in the phosphorylation of serine and threonine amino acid residues, a critical process for the activation and inactivation of many proteins.

Therapeutic significance:

Understanding the role of Serine/threonine-protein kinase 35 could open doors to potential therapeutic strategies. Its involvement in key cellular processes makes it a target of interest for drug discovery efforts aimed at treating various diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.